BioDuro-Sundia, an Advent International portfolio company is a trusted, leading contract research development, manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 10 global sites across 7 cities.
Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one stop shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Science-driven, customer-oriented, flexible, people focused culture enables us to provide top-tier integrated, fast and flexible tailored services to our customers to meet their unique needs and accelerate development timeline.
Acquired two US-based commercial drug product manufacturing facilities with over 100,000 sq. ft. and 4 billion doses capacity annually
Completed 1st GMP drug product manufacturing at new R&D center in Wuxi
Acquired Sundia to become BioDuro-Sundia, one of the largest CRDMOs worldwide
300,000 sq. ft. Wuxi facility opened with integrated capabilities across discovery and GMP manufacturing
Advent bought majority of stake and partnered with BioDuro
Acquired Molecular Response (“Tumor Bank”)
BioDuro reacquired from PPD; BioDuro and Formex merged to enable broad range of service offering
Formex joined Bridgewest Group, operating in a 44,000 sq. ft. GMP facility
93,000 sq. ft. Shanghai facility (72,000 sq. ft. lab) opened to meet growing client demand
BioDuro acquired by PPD
Sundia merged with United Pharma
100,000 sq. ft. Beijing site opened –first site in China
BioDuro founded in San Diego by Biotech Investment Group with operations commenced in Beijing
At BioDuro-Sundia, we operate with integrity and strict standards of law and business ethics, which are our fundamental guidelines in all locations. We adhere the business ethics of legal compliance, integrity and self-discipline, and strictly comply with laws and regulations related to corporate governance and the Corporate Governance Code, and have zero tolerance for any form of corruption. We have built a strong security infrastructure that protects and preserves the intellectual property and data of our customers; We are implementing green manufacturing and sustainable operations across our business units, helping to improve the environment and our communities.